Evidence map›Paper›PMID 41444589›Full record

ReviewVirology journal2025

Learning from nature: HIV elite controllers as blueprints for a functional cure.

V Kalidasan, Kumitaa Theva Das

Abstract readReview
In one paragraph

Review in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Early immune responses anticipate HIV rebound and precede viral control.bioRxiv : the preprint server for biology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

V KalidasanInstitute for Research in Molecular Medicine, Universiti Sains Malaysia, Pulau Pinang, Malaysia.
Kumitaa Theva DasInstitute for Research in Molecular Medicine, Universiti Sains Malaysia, Pulau Pinang, Malaysia. kumitaa@usm.my.

Funding

Universiti Sains Malaysia R501-LR-RND003-0001458-0000
6 · The paper itself

Abstract

Antiretroviral therapy (ART) has transformed HIV infection into a manageable chronic condition but remains non-curative and requires lifelong adherence. Rare cases of long-term remission following stem cell transplantation (SCT) have demonstrated the possibility of viral eradication, yet this approach is not scalable or safe for global implementation. A unique subset of people living with HIV, known as elite controllers (ECs), can naturally suppress replication-competent HIV without ART, often for decades, while maintaining stable CD4 + T cell counts and showing no signs of disease progression. Their ability to sustain treatment-free viral suppression provides compelling evidence that durable remission is biologically achievable, offering a model for cure research. This review synthesizes current evidence on the biology of ECs, encompassing viral, intrinsic antiviral, genetic, and immune mechanisms that underlie natural control. It also examines demographic and clinical characteristics, landmark case reports, and the broader public health implications of elite control. Finally, insights from EC biology are discussed in relation to translational strategies such as gene editing, immune modulation, therapeutic vaccination, and reservoir-targeting approaches designed to mimic or reinforce natural control mechanisms. Understanding the determinants of viral suppression in ECs provides a biological blueprint for the development of a functional cure. As the field advances toward scalable, safe, and durable remission strategies, lessons from ECs remain central to achieving long-term viral control and ultimately ending the HIV epidemic.

Indexed as

HIV-1HIV InfectionsHIV Long-Term SurvivorsCD4 Lymphocyte CountCD4-Positive T-LymphocytesHumansElite controllersFunctional cureHIV/AIDSNatural immunityViral reservoirs

Identifiers

PMID41444589
PMCPMC12849495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.